Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Senate Committee Signals Approval Of Seema Verma To Run CMS, But Most Dems Will Vote 'No'

Executive Summary

At a Senate Finance Committee markup on the confirmation of Seema Verma to become CMS administrator, a majority of senators signaled approval of Verma, but most Democrats said they will vote "no" in response to their dissatisfaction with her written answers on issues, including past conflicts-of-interest, ACA repeal and Medicaid changes. A binding committee vote is expected March 2.

You may also be interested in...

US CMS Nominee Verma Advances To Senate Floor On Narrow Vote

Seema Verma, President Trump's nominee to lead the Medicare agency, was approved by the Senate Finance Committee March 2 on a narrow 13-12 vote; her confirmation will now be taken up by the full Senate. Questions remain about Verma's viewpoints related to replacement of the Affordable Care Act and on promoting alternative Medicare value-based payment models.

CMS Nominee Seema Verma Urges Caution On Competitive Bidding Program

Seema Verma, President Trump’s pick to run the US Medicare agency, told the Senate Finance Committee that rural areas should not have to comply with CMS’ medical supplies competitive-bidding program if it is not a good fit. Verma was also questioned on changes she might make to the Affordable Care Act and the Medicare program, but did not offer many specifics.

Industry 'Encouraged' By Trump Exec Order To Undo ACA, Device Tax

Industry cheered one of President Trump's first executive orders filed Jan. 20, calling on HHS and others in the executive branch to "waive, defer, grant exemptions" from Affordable Care Act provisions for industry imposing burdens on them, including the costs of taxes and fees on "makers of medical devices."

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts